Mayer Brown and Latham & Watkins are advising on the $2.6 billion acquisition by Nestlé SA, the Swiss-based international food giant, of Aimmune Therapeutics, a U.S.-based specialist in treatments for food allergies.

Aimmune, based in Brisbane, California, has developed the drug Palforzia, the first and only Food and Drug Administration-approved treatment to help reduce the severity of the allergic reaction to peanuts in children aged 4 through 17.